The main purpose of Hera-MI is to use Artificial Intelligence to help
early-stage breast cancer diagnosis in order to optimize patient care.
Breast cancer is the most commonly occurring cancer in women with over 60,000 new cases in France and 2 million worldwide each year. However, when breast cancer is detected at an early stage, nearly 90% of cases go into remission.
2019 is going to be the year of AI in the healthcare industry and especially in medical imaging. AI will start penetrating medical imaging facilities. Over the past few years, the volume of medical images has been constantly growing. Indeed, medical equipment now generate 1,000 to 1,500 images per medical exam, which is 40 times more than 30 years ago. Radiologists are now dealing with about 50,000 images a day. However, the treatment of such amount of data exceeds the human brain capacity. This is becoming a risk. Indeed, radiologists can see their analysis reduced by the huge amount of data they have to manage. Intense stress and fatigue combined with the fear of being mistaken can negatively affect radiologist’s diagnosis quality. 3D mammography (Digital Breast Tomosynthesis) has drastically increased the volume of images as well as the amount of information radiologists must review.
Considering these facts, our main goal is to use AI to help promote the early diagnosis of breast cancer. AI can analyze a huge quantity of data in a very short time. AI will help radiologists detect anomalies that can be sometimes hard to see.
Hera-MI has developed Breast-SlimView: a patented software for reading and clinical decision support in 2D and 3D mammography.
Breast-SlimView offers innovative and disruptive reading support where only relevant information is displayed. Radiologists can free themselves from irrelevant information. They will be able to visualize at a glance potentially suspicious areas.